Latest:
Board Review Resources 2024
Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Fay Kastrinos, MD, MPH
Latest:
Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive Considerations
In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.
Meghan K. Berkenstock, MD
Latest:
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Meghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.
Gary Doherty, MRCP, PhD, Cambridge University Hospitals NHS Foundation Trust
Latest:
EGFR+ NSCLC: Advice for Community Oncologists
A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Panagiotis J. Vlachostergios, MD, PhD
Latest:
Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma Landscape
Monoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.
Manmeet S. Ahluwalia, MD, MBA, FASCO
Deputy Director, Chief Scientific Officer, Chief of Medical Oncology, Fernandez Family Foundation Endowed Chair in Cancer Research – Miami Cancer Institute, part of Baptist Health South Florida
Latest:
2024 Outlook on Cancer Care: Striving to Overcome the Challenges
Although novel therapies have improved cancer care, cancer diagnoses have increased, with more than 2 million new cases estimated for 2024.
David D'Ambrosio, MD
Latest:
Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer
David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.
Bernard Doger de Spéville, MD, PhD
Latest:
Dr Doger de Spéville on Key Efficacy Findings From Part C of TACTI-002 in HNSCC
Bernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma.
Surbhi Sidana, MD
Latest:
Dr Sidana on CAR T-cell Therapy in Patients With R/R Myeloma and Renal Impairment
Surbhi Sidana, MD, discusses the unmet needs for patients with relapsed/refractory multiple myeloma who could be candidates for CAR T-cell therapy but have impaired renal function, and how clinical trials for these therapies have excluded this subset of patients.
Gregory Peter Kalemkerian, MD
Latest:
Dr Kalemkerian on Unmet Needs With the Use of Chemoimmunotherapy in ES-SCLC
Gregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.